All News

Experts weigh GLP-1 therapy's promise for PMOS against the risks of overly rapid weight loss in teenagers.

Experts break down which labs actually change PMOS management and how to avoid diagnostic pitfalls.

US clinicians increasingly prescribe GLP-1 drugs to young children with obesity, although overall use remains limited and access disparities persist.

Most patients meet PMOS in a primary care office first. Our experts map the referral threshold and argue insulin resistance — not just androgens — should drive how aggressively PCPs treat.

FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.

Our expert panel walks through the 2-criteria threshold for adolescents, the "at risk" category, and why untreated menstrual irregularity carries real long-term consequences.

A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.

Cindy Hou, DO, joins Jubril Oyeyemi, MD, to discuss how primary care clinicians can prevent, recognize, and manage sepsis.

Recent FDA actions include updates in HIV, influenza, narcolepsy, type 2 diabetes, and RSV prevention in high-risk children.

A global consensus just renamed PCOS to PMOS. Our experts explain why the shift moves care beyond the ovaries — and what it means for how clinicians talk to patients today.

FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.

The proportion of US women aged 21 to 29 years who have never received cervical cancer screening more than doubled between 2005 and 2023, according to new data.

Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.

Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.

FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.

FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.

Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.

Plasma p-tau217 levels helped estimate 5- and 10-year cognitive impairment risk in older adults without memory or thinking symptoms.